Navigation Links
Bentley Late Breaking Abstract Accepted for Poster Presentation at,American Diabetes Association Scientific Sessions

uent periodic reports filed with the Securities and Exchange Commission. Bentley cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and Bentley undertakes no obligation to update or revise the statements, except as may be required by law.

Contact

Bentley Pharmaceuticals, Inc.
Jean DeRoche, 603-658-6136
jderoche@bentleypharm.com
or
Sharon Merrill Associates
Jim Buckley, 617-542-5300
bnt@investorrelations.com


'"/>




Page: 1 2 3

Related medicine technology :

1. Bentley Reports Positive Results with Nasulin Intranasal Insulin Spray at the American Diabetes Association Meeting
2. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
3. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
4. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
5. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
6. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
7. Everest Data on Short- and Long-Term Use of Otsukas Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACCs Late Breaking Clinical Trials
8. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
9. Savient Pharmaceuticals Announces Acceptance of Two Gout-Related Abstracts for Poster Presentation at the European League Against Rheumatism (EULAR) 2007 Annual Congress
10. OXiGENE Abstracts Published in ASCO Program
11. Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
Post Your Comments:
(Date:12/1/2008)... Md., Dec. 1 Vanda Pharm...ion in The Lancet , one of the world,s leading me...novel circadian regulator, experimental compound t...am et al(1) is entitled "Melatonin agonist tasimel...time shift: two randomised controlled multicentre ...
(Date:12/1/2008)...tudy shows the Prox1 gene is a two-way switch that...s to be reprogrammed so that they lose their ident..., , MEMPHIS, Tenn., Dec. 1 /PRNewswire-USNew...rch Hospital have discovered that a certain differ...ity that it requires the constant expression of a ...
(Date:12/1/2008)...ec. 1 GeoVax Labs, Inc.,...echnology company developing,human vaccines for d...rus) and,other infectious agents, announced today...ials will take place in twelve sites across North ...collaboration with The National Institutes of,Hea...
(Date:11/28/2008)...IS, Nov. 28 Eli Lilly an...mental New Drug Application (sNDA) from,the U.S. ... (duloxetine HCl),for the management of chronic p...he first half of 2009, adding data from a recently...is pain of the knee. , The decision does no...
Breaking Medicine Technology:Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Chocolate Milk 3A The Official Drink of Halloween 2863 1Chocolate Milk 3A The Official Drink of Halloween 2863 2Chocolate Milk 3A The Official Drink of Halloween 2863 3Chocolate Milk 3A The Official Drink of Halloween 2863 4Bioponic Phytoceuticals Retains OTC Financial Network for Investor Relations 2858 1Bioponic Phytoceuticals Retains OTC Financial Network for Investor Relations 2858 2Bioponic Phytoceuticals Retains OTC Financial Network for Investor Relations 2858 3Hyperion Therapeutics Inc Announces Senior Management Team and 2415M Financing Event 1052 1Hyperion Therapeutics Inc Announces Senior Management Team and 2415M Financing Event 1052 2Hyperion Therapeutics Inc Announces Senior Management Team and 2415M Financing Event 1052 3Hyperion Therapeutics Inc Announces Senior Management Team and 2415M Financing Event 1052 4Hyperion Therapeutics Inc Announces Senior Management Team and 2415M Financing Event 1052 5Hyperion Therapeutics Inc Announces Senior Management Team and 2415M Financing Event 1052 6Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 445 1Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 445 2Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 445 3Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 445 4Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 445 5Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 445 6
...duces TNF-alpha Production Through Inhibition,of P...ewswire/ -- Anacor,Pharmaceuticals, a privately he...ults from its placebo-controlled Phase 1 trial of,...estigation for,the treatment of psoriasis. The tri...ty comparable to existing topical,treatments for p...
... York, June 06, 2007 /PRNewswire-FirstCall/,-- XTL...as,completed the analysis of results from a Phase ...ronic Hepatitis C. This Phase I,trial was a placeb...hich evaluated the safety, tolerability and antivi...125. The study enrolled 56,patients into seven coh...
Other Medicine Technology:Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory,Compound, Shows Efficacy in Psoriasis 2XTL Provides Update on Phase I Clinical Trial of XTL-2125 2XTL Provides Update on Phase I Clinical Trial of XTL-2125 3
(Date:12/2/2008)...iginal Special Features MLS Stars and Promotes Hea...re/ -- Juniper Content Corporation,s (OTC Bulleti... fastest-growing Spanish-language children,s netwo...al special Juega Como un MLS Pro , the climax of ...ague Soccer, on Sunday, December 7th at 7 PM EST. ...
(Date:12/2/2008)...CKVILLE, Md., Dec. 2 Neu...oday that it has entered into a,collaboration wit...aiwan, to,advance development of Neuralstem,s hum...ollaboration will focus on Amyotrophic Lateral Scl...nn-Zong Lin, MD, PhD as principle,investigator. ,...
(Date:12/2/2008)...LVERN, Pa., Dec. 2 Arlington Medic...intelligence for the pharmaceutical and diagnostic...sen Pharmaceuticals, Levaquin,is the preferred qu...eral,medical-surgical hospitals in the United Sta..., sinus, skin and urinary tract infections caused ...
(Date:12/2/2008)...rcentage of Biologic-Treated Psoriasis Patients Wi...Decision Resources , , WALTHAM, Mass., Dec....world,s leading research and advisory firms for ph...logic agents, particularly Centocor/Janssen-Cilag,...e moderate to severe psoriasis drug market to more...
Breaking Medicine News(10 mins):Health News:Sorpresa! Premieres Juega Como un MLS Pro 2Health News:Neuralstem Collaborates with Hospital in Taiwan to Develop Additional ALS Stem Cell Clinical Trials 2Health News:Levaquin is the Preferred Quinolone Among More Than Half of All General Medical-Surgical Hospitals in the United States 2Health News:Biologic Drugs, Particularly Centocor/Janssen-Cilag's Stelara and Abbott/Eisai's Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017 2
...alian Medical Association (AMA) has issued a warni...tly trained doctors //in the future due to a lack ...MA president has written to the federal MPs and se... in place that would help to deal with the increas...
... health authorities are reconsidering recent chang...doctors of Indian origin ineligible// to work in t...th (DoH) and the home office had put in place a ne... to prove that no suitable candidate was available...
...me the scarcity of doctors in rural areas, the Goa...assing out of state-run medical colleges// to serv...ratapsingh Rane said. The state cabinet decided ...d to be signed by the medical students to serve in...
...rs have found for the first time that human embryo...coaxed to develop into mature T-cells//, raising h...s from the UCLA AIDS Institute and the Institute f... found that it is possible to convert human embryo...
Other Medicine News:Health News:Britain Reconsidering New Visa Rules for Indian Doctors 2Health News:T-cells Developed from Human Embryonic Stem Cells 2
Portable - Battery Powered (6 size AA required). Fast, Lightweight Strain Gage Mechanism. Unit conversion (g, ct, oz, ozt, GN, dwt, mom, dwt, tael), Specific Gravity calculation, Piece Counting and P
Portable - Battery Powered (6 size AA required). Fast, Lightweight Strain Gage Mechanism. Unit conversion (g, ct, oz, ozt, GN, dwt, mom, dwt, tael), Specific Gravity calculation, Piece Counting and P
Small, comes in a compact carrying case, carrying pouch included.
60 month warranty, constructed entirely of aluminum alloy, allows the selection of 11 units of measure.
Medicine Products: